EA201691397A1 - Хинолиновые ингибиторы киназы - Google Patents

Хинолиновые ингибиторы киназы

Info

Publication number
EA201691397A1
EA201691397A1 EA201691397A EA201691397A EA201691397A1 EA 201691397 A1 EA201691397 A1 EA 201691397A1 EA 201691397 A EA201691397 A EA 201691397A EA 201691397 A EA201691397 A EA 201691397A EA 201691397 A1 EA201691397 A1 EA 201691397A1
Authority
EA
Eurasian Patent Office
Prior art keywords
quinoline
kinase inhibitors
compounds
aak1
adapter
Prior art date
Application number
EA201691397A
Other languages
English (en)
Inventor
Ричард А. Харц
Виджай Т. Ахуджа
Джон Е. Мэйкор
Джоанн Дж. Бронсон
Бирешвар Дасгупта
Кэролин Дайан Дзиерба
Сушеел Джетхананд Нара
Махесваран Сивасамбан Каратолувху
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA201691397A1 publication Critical patent/EA201691397A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Настоящее изобретение в целом относится к соединениям, которые могут ингибировать AAK1 (адаптер-ассоциированную киназу 1), к композициям, содержащим такие соединения, и к способам ингибирования AAK1.
EA201691397A 2014-01-31 2015-01-23 Хинолиновые ингибиторы киназы EA201691397A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461934152P 2014-01-31 2014-01-31
PCT/US2015/012649 WO2015116492A1 (en) 2014-01-31 2015-01-23 Quinoline-based kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201691397A1 true EA201691397A1 (ru) 2016-11-30

Family

ID=52474081

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691397A EA201691397A1 (ru) 2014-01-31 2015-01-23 Хинолиновые ингибиторы киназы

Country Status (9)

Country Link
US (1) US9932320B2 (ru)
EP (1) EP3099673B1 (ru)
JP (1) JP6441947B2 (ru)
CN (1) CN106132951B (ru)
CA (1) CA2937501A1 (ru)
EA (1) EA201691397A1 (ru)
ES (1) ES2701903T3 (ru)
MX (1) MX2016009352A (ru)
WO (1) WO2015116492A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019475A1 (en) 2013-07-08 2016-05-18 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
ES2678877T3 (es) 2013-10-11 2018-08-20 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
JP6411541B2 (ja) 2014-04-02 2018-10-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ビアリールキナーゼ阻害剤
US10174044B2 (en) * 2015-04-10 2019-01-08 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
US10544120B2 (en) 2015-10-01 2020-01-28 Bristol-Myers Squibb Company Biaryl kinase inhibitors
ES2767776T3 (es) 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
US20190071416A1 (en) * 2015-10-09 2019-03-07 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics
EP3260445A1 (en) 2016-06-24 2017-12-27 Universität Konstanz Compounds for use as an anti-bacterial or anti-fungal agent and as a zinc sensor
CN107501180B (zh) * 2017-09-13 2020-06-05 新乡医学院 一种喹啉-4-甲酰胺类化合物的合成方法
EP3502095A1 (en) 2017-12-22 2019-06-26 Universität Konstanz Compound for use against pathogenic neisseria and haemophilus species and moraxella catarrhalis
CN109734705B (zh) * 2019-02-01 2021-09-28 浙江工业大学 一种经脱卤烷基化制备n-杂环芳烃衍生物的方法
WO2021050913A1 (en) * 2019-09-12 2021-03-18 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN113387965A (zh) * 2021-06-17 2021-09-14 南京邮电大学 一种有机电子受体材料及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1276739A2 (en) 2000-04-24 2003-01-22 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
SG11201405561RA (en) * 2012-03-09 2014-10-30 Lexicon Pharmaceuticals Inc PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
AU2013230119B2 (en) * 2012-03-09 2017-02-23 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
US8703953B2 (en) * 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
WO2013134336A2 (en) * 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
US20170239249A1 (en) 2014-09-30 2017-08-24 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors

Also Published As

Publication number Publication date
JP2017504652A (ja) 2017-02-09
JP6441947B2 (ja) 2018-12-19
US20160332985A1 (en) 2016-11-17
CN106132951B (zh) 2019-02-12
MX2016009352A (es) 2016-10-13
ES2701903T3 (es) 2019-02-26
WO2015116492A1 (en) 2015-08-06
EP3099673A1 (en) 2016-12-07
US9932320B2 (en) 2018-04-03
EP3099673B1 (en) 2018-09-26
CN106132951A (zh) 2016-11-16
CA2937501A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
EA201691916A1 (ru) Биарильные ингибиторы киназы
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
EA201890926A1 (ru) ТРИАЗОЛОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
MY194262A (en) Inhibitors of ret
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201892123A1 (ru) 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
NZ725917A (en) Novel polymerase-i inhibitors, uses and methods for making them
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201491647A1 (ru) Основанные на арилэфирах ингибиторы киназ
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
EA201990159A1 (ru) Биарилметильные гетероциклы
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).